JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Where Today's News Shapes Tomorrow
